Calamos Advisors LLC Increases Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Calamos Advisors LLC boosted its stake in ADMA Biologics, Inc. (NASDAQ:ADMAFree Report) by 7.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 425,906 shares of the biotechnology company’s stock after buying an additional 28,154 shares during the period. Calamos Advisors LLC’s holdings in ADMA Biologics were worth $7,304,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of ADMA. Hollencrest Capital Management bought a new position in shares of ADMA Biologics in the 3rd quarter worth approximately $30,000. Larson Financial Group LLC bought a new position in ADMA Biologics in the third quarter worth $31,000. GAMMA Investing LLC lifted its position in ADMA Biologics by 106.6% during the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 967 shares during the period. National Bank of Canada FI purchased a new position in ADMA Biologics during the third quarter valued at $35,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of ADMA Biologics during the 3rd quarter valued at $62,000. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Price Performance

ADMA opened at $16.90 on Wednesday. ADMA Biologics, Inc. has a 1 year low of $5.02 and a 1 year high of $23.64. The stock has a 50-day moving average price of $17.90 and a 200-day moving average price of $17.66. The firm has a market cap of $3.99 billion, a PE ratio of 60.36 and a beta of 0.75. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

ADMA Biologics (NASDAQ:ADMAGet Free Report) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.02. The firm had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same quarter in the prior year, the firm posted $0.01 earnings per share. Sell-side analysts predict that ADMA Biologics, Inc. will post 0.51 earnings per share for the current fiscal year.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the company’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the transaction, the chief financial officer now owns 199,433 shares in the company, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 3.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Raymond James increased their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th. HC Wainwright raised their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th.

Check Out Our Latest Analysis on ADMA

ADMA Biologics Profile

(Free Report)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Featured Stories

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics, Inc. (NASDAQ:ADMAFree Report).

Institutional Ownership by Quarter for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.